Antibody Drug Conjugates in Non-Small Cell Lung Cancer: an emerging therapeutic approach

The current standard-of-care for the treatment of advanced non-small cell lung cancer (NSCLC) incorporates targeted therapies, immune-checkpoint inhibitors (ICI) and systemic chemotherapy. Antibody-drug conjugates (ADC) are a class of anti-cancer therapy capable of transporting cytotoxic drugs directly to tumour cells, thus harnessing the strengths of both cytotoxic chemotherapy and targeted therapy.In this review we provide a comprehensive review the design, mode of action, and mechanisms of resistance to ADCs in NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research